ArticleEJIFCC2025
Evaluation of Adropin, Irisin and Cytokeratin 18 as Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Clinical Study.
Article in EJIFCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become the leading cause of chronic liver disease globally, affects more than one-third of the adult population and includes a spectrum of conditions ranging from simple steatosis of liver to metabolic dysfunction-associated steatohepatitis (MASH), progressive fibrosis, cirrhosis and, in some cases, hepatocellular carcinoma. Early detection and accurate staging are important to prevent disease progression and studies have recently identified metabolic and apoptotic markers such as Adropin, a peptide hormone secreted by the liver that is involved in energy homeostasis; Irisin, a myokine that is linked to exercise and metabolic regulation; and CK-18, a biomarker of hepatocyte apoptosis.Methods: Using FibroScan for the diagnosis and staging of MASLD, CAP scores were used for steatosis and liver stiffness measurements for fibrosis. Quantification of serum adropin, irisin, and CK-18 was done, and independent t-tests, correlation analysis, and ROC curve analysis were used for statistical analysis to assess the diagnostic potential. Results: Adropin levels were lower in MASLD cases than in controls and decreased further with the severity of the disease. The association was highly significant (p < 0.001), indicating a very high negative correlation between Adropin levels and hepatic dysfunction. Levels of CK-18 were greatly increased in MASLD patients and were highly positively correlated with the degrees of fibrosis and steatosis (p < 0.001), which supports the hypothesis that it is a marker of hepatocyte apoptosis. Conclusion: The significant changes in their levels observed in MASLD patients suggest their possible application in multimarker diagnostic strategies. Nonetheless, the inconsistent behavior of Irisin in this study requires more conclusive evidence from future studies involving larger samples. Such biomarkers may help in identifying the disease at an early stage and improve the management of the disease.
Indexed as
Identifiers
41459170PMC12743348What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.